Nano-magnetite/ionic liquid crystal modifiers of carbon nanotubes composite electrode for ultrasensitive determination of a new anti-hepatitis C drug in human serum
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Journal of Electroanalytical Chemistry
- Vol. 823, 296-306
Abstract
No abstract availableKeywords
Funding Information
- Cairo University
This publication has 43 references indexed in Scilit:
- Current therapy for chronic hepatitis C: The role of direct-acting antiviralsAntiviral Research, 2017
- Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2017
- Development and Validation of the Chiral HPLC Method for Daclatasvir in Gradient Elution Mode on Amylose-Based Immobilized Chiral Stationary PhaseChromatographia, 2016
- A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2016
- Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2015
- Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis CDrugs, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeProceedings of the National Academy of Sciences, 2013
- Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus InfectionClinical Gastroenterology and Hepatology, 2010
- Perspectives on Fibrosis Progression in Hepatitis C: An à la Carte Approach to Risk Factors and Staging of FibrosisAntiviral Therapy, 2009